賽升藥業(300485.SZ)：以600萬元認購拜西歐斯註冊資本
格隆匯5月17日丨賽升藥業(300485.SZ)公佈，公司於2021年5月17日召開的第四屆董事會第五次會議審議通過了《關於簽訂股權轉讓協議暨關聯交易的議案》，公司於近日與拜西歐斯(北京)生物技術有限公司(“拜西歐斯”)、魏輝(“轉讓方”)簽署了《股權轉讓協議》。公司以人民幣600萬元認購拜西歐斯註冊資本30.755萬元，持有拜西歐斯2.35%的股權。
拜西歐斯是一家致力於神經系統疾病領域創新藥物研究、開發與轉化的國家高新技術企業。產品類型以多肽藥物和大分子藥物研發為主。拜西歐斯開發的治療急性缺血性腦卒中藥物注射用BXOS110，是一款在研的突觸後緻密蛋白(PSD-95)抑制劑，可阻斷一種名為PDS-95的破壞性蛋白質，這種蛋白是觸發細胞死亡信號的穀氨酸受體與神經元一氧化氮合酶(nNOS)之間的重要中介，在卒中時會引發一系列生化活性，從而產生一氧化氮(NO)。NO是自由基，在血液供應受阻時會破壞神經元。PSD-95抑制劑與其他分子(例如nNOS)的結合，從而抑制細胞死亡信號。目前在全球尚無同類產品上市，相同靶點的藥物ESCAPE-NA1國際多中心III期臨牀試驗結果取得科學突破性意義，證明了藥物治療對卒中症狀出現後長達12小時的急性中風人羣具有重要作用。對於未使用阿替普酶治療的預先指定亞組中接受Nerinetide獲益的患者規模、持續時間及其長期治療窗口等結果超過預期。注射用BXOS110在體內和體外模型上也顯示出與Nerinetide同等或優秀的神經保護作用，並且安全性好。該藥未來上市，將填補國內外該領域的空白，具有廣闊市場前景和良好社會效應，目前注射用BXOS110已獲得臨牀許可。
此次合作與公司戰略發展方向具有較強協同性，有利於資源整合和利用。未來公司在BXOS110項目臨牀樣品委託生產、產品獲批上市後的委託生產以及銷售和推廣工作，於同等條件下，擁有優先承接的權利。此次合作將拓展公司戰略發展布局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
